Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) insider Christopher D. Roberts sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, April 5th. The shares were sold at an average price of $25.54, for a total transaction of $63,850.00. Following the completion of the transaction, the insider now directly owns 5,700 shares of the company’s stock, valued at approximately $145,578. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of BDTX stock opened at $24.26 on Thursday. The company has a market capitalization of $876.71 million and a PE ratio of -4.01. The firm has a fifty day simple moving average of $25.77 and a 200-day simple moving average of $29.85. Black Diamond Therapeutics, Inc. has a twelve month low of $21.04 and a twelve month high of $46.25.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its earnings results on Wednesday, March 24th. The company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). As a group, research analysts forecast that Black Diamond Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

BDTX has been the subject of a number of analyst reports. Canaccord Genuity reissued a “buy” rating and issued a $50.00 price objective on shares of Black Diamond Therapeutics in a research report on Tuesday, January 19th. HC Wainwright reissued a “buy” rating and issued a $53.00 price objective on shares of Black Diamond Therapeutics in a research report on Friday, March 26th. Zacks Investment Research raised shares of Black Diamond Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Wedbush assumed coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, January 6th. They set an “outperform” rating and a $45.00 price target for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $48.40.

Hedge funds have recently made changes to their positions in the company. Penserra Capital Management LLC purchased a new position in shares of Black Diamond Therapeutics in the fourth quarter valued at $26,000. Pacer Advisors Inc. acquired a new stake in Black Diamond Therapeutics in the fourth quarter valued at $35,000. Principal Financial Group Inc. acquired a new stake in Black Diamond Therapeutics in the fourth quarter valued at $238,000. Citigroup Inc. raised its holdings in Black Diamond Therapeutics by 161.6% in the fourth quarter. Citigroup Inc. now owns 7,470 shares of the company’s stock valued at $239,000 after acquiring an additional 4,614 shares in the last quarter. Finally, Raymond James & Associates raised its holdings in Black Diamond Therapeutics by 4.7% in the third quarter. Raymond James & Associates now owns 7,493 shares of the company’s stock valued at $227,000 after acquiring an additional 333 shares in the last quarter. Institutional investors and hedge funds own 65.78% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase.

Read More: What causes a stock to be most active?

Insider Buying and Selling by Quarter for Black Diamond Therapeutics (NASDAQ:BDTX)

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.